Dynamic Technology Lab Private Ltd Sells 11,241 Shares of Axonics, Inc. (NASDAQ:AXNX)

Dynamic Technology Lab Private Ltd lessened its holdings in Axonics, Inc. (NASDAQ:AXNX) by 45.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 13,600 shares of the company’s stock after selling 11,241 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Axonics were worth $946,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AXNX. Algert Global LLC grew its position in shares of Axonics by 117.5% during the third quarter. Algert Global LLC now owns 73,627 shares of the company’s stock worth $5,124,000 after purchasing an additional 39,780 shares in the last quarter. Citigroup Inc. boosted its position in shares of Axonics by 7.8% during the third quarter. Citigroup Inc. now owns 647,152 shares of the company’s stock worth $45,042,000 after acquiring an additional 46,841 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Axonics by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 419,985 shares of the company’s stock worth $29,231,000 after acquiring an additional 6,115 shares during the last quarter. Intech Investment Management LLC purchased a new position in Axonics during the third quarter valued at $907,000. Finally, Alpine Associates Management Inc. increased its holdings in Axonics by 3.3% in the 3rd quarter. Alpine Associates Management Inc. now owns 2,178,157 shares of the company’s stock valued at $151,600,000 after acquiring an additional 69,286 shares during the last quarter. 99.48% of the stock is owned by institutional investors.

Axonics Stock Performance

Shares of NASDAQ:AXNX opened at $70.98 on Thursday. The company has a market cap of $3.63 billion, a price-to-earnings ratio of -591.45 and a beta of 0.82. Axonics, Inc. has a 12 month low of $55.09 and a 12 month high of $71.05. The company has a 50-day moving average price of $70.17 and a 200 day moving average price of $68.78.

Analysts Set New Price Targets

Separately, Needham & Company LLC restated a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Axonics has an average rating of “Hold” and an average price target of $71.00.

Insider Activity

In related news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the sale, the chief financial officer now owns 40,362 shares in the company, valued at approximately $2,801,526.42. This represents a 6.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.